| abstract |
The present invention relates to novel nitrosated and / or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and at least one nitrosated and / or nitrosylated cardiovascular compound, optionally at least one nitric oxide donor And / or novel compositions comprising at least one therapeutic agent are described. The invention also includes at least one cardiovascular compound of the invention, which may optionally be nitrosated and / or nitrosylated, and optionally at least one nitric oxide donor compound and / or at least one therapeutic agent. Novel compositions and kits that may be provided are provided. The present invention also treats (a) cardiovascular disease; (b) treats renovascular disease; (c) treats diabetes; (d) treats disease resulting from oxidative stress; (e) Treat endothelial dysfunction; (f) treat disease caused by endothelial dysfunction; (g) treat cirrhosis; (h) treat pre-eclampsia; (j) treat osteoporosis; and (k ) Provide a method of treating nephropathy. Nitrosated and / or nitrosylated cardiovascular compounds are nitrosated and / or nitrosylated P-adrenergic antagonists, nitrosated and / or nitrosylated angiotensin converting enzyme (ACE) inhibitors, nitrosated and / or nitrosylated anti-hyperlipids Preference is given to diastolic compounds and nitrosated and / or nitrosylated antithrombotic and vasodilatory compounds. |